| dc.creator |
Solak, Yalcin |
|
| dc.creator |
Siriopol, Dimitrie |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.creator |
Covic, Adrian |
|
| dc.creator |
Yazici, Dilek |
|
| dc.creator |
Afsar, Barış |
|
| dc.creator |
Aslan, Gamze |
|
| dc.date |
2016-12-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:29:01Z |
|
| dc.date.available |
2021-12-03T11:29:01Z |
|
| dc.identifier |
57dfd4f8-828d-456f-adb1-0a88d34038da |
|
| dc.identifier |
10.1007/s11255-016-1387-8 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/57dfd4f8-828d-456f-adb1-0a88d34038da/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/91976 |
|
| dc.description |
Chronic kidney disease mineral and bone disorder (CKD-MBD) is associated with increased morbidity and mortality. Several cross-sectional studies investigated the association of serum sclerostin levels with mortality and vascular calcification. We aimed to investigate the effect of sclerostin on cardiovascular events (CVE), all-cause/cardiovascular mortality and vascular calcification in patients with CKD through systematic review and meta-analysis. The primary outcome was the association between sclerostin level and development of fatal and nonfatal CVE and all-cause mortality. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis |
|
| dc.type |
info:eu-repo/semantics/article |
|